NCT07001800Phase 2, phase 3Recruiting

Ataciguat for Slowing the Progression of Moderate Calcific Aortic Valve Stenosis: A Randomized, Placebo Controlled Study

Study sponsor: Kardigan, Inc. · KARD

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2028-08-31Estimated
Enrollment · participants1276Estimated
Source updated2026-07-06Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 3 fields changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: (Part A) Change in Aortic Valve Calcium (AVC) from baseline to Week 24 Measure: (Part B Dual-Primary) Percent change in AVA as measured by echocardiogram from baseline to Week 48 Measure: (Part B Dual-Primary) Change in peak VO2 from baseline to Week 48. After: Measure: (Part A) Change in Aortic Valve Calcium (AVC) score as assessed by non-contrast CT from baseline to Week 24 Measure: (Part B Dual-Primary) Percent change in Aortic Valve Area (AVA) as measured by echocardiogram from baseline to Week 48 Measure: (Part B Dual-Primary) Change in peak VO2 by CPET from baseline to Week 48.

Planned enrollment decreased by 134 participants

Before: 1410 participants (planned). After: 1276 participants (planned).

Phase changed

Before: PHASE3. After: PHASE2, PHASE3.

Check registry source

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview